Clinical trial results from MASCOT Trial evaluating AngioSculpt PTA Scoring Balloon Catheter announced
October 25, 2017
???We are very encouraged by the positive clinical data from MASCOT,??? said Thomas R. Trotter, President and CEO of AngioScore. ???Sales of AngioSculpt devices for the treatment of PAD have been growing rapidly, and this important new clinical data provides physicians worldwide with further confirmation of its usefulness and effectiveness.???
???PAD is one of the fastest-growing segments of the Endovascular Market, with an estimated two million annual procedures worldwide. In addition, longer AngioSculpt devices (?‰? 10 cm) currently in development have the potential of extending the usefulness of this technology to patients with even more diffuse SFA disease.???
The AngioSculpt?® Scoring Balloon Catheter represents the next generation in angioplasty catheters. Its innovative nitinol scoring element provides unique anti-slipping properties while circumferentially dilating plaque, providing a precise and predictable dilatation across a wide range of lesion types. The AngioSculpt provides the versatility and effectiveness of a new technology together with the simplicity and deliverability of a high-performance balloon catheter.
SOURCE AngioScore, Inc.